Also trades as: 0I3Q.L (LSE) · $vol 0M
CORT Smart Money
Corcept Therapeutics Incorporated
1W: -24.8%
1M: -24.2%
3M: -5.8%
YTD: +129.3%
1Y: +20.8%
3Y: +213.7%
5Y: +346.0%
$87.59
+0.47 (+0.53%)
Weekly Expected Move ±11.6%
$66
$76
$86
$96
$106
Credit Risk of going bust: lower than 85% of companies Debt: 0.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down more than 99.9%), Corcept Therapeutics Incorporated would be worth roughly what it owes.
Total debt $9.4M against a stock market value of $9.47B.
Distance to default 11.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.7M (short-term plus half of long-term), stock volatility 64.9%; Altman Z'' 8.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down more than 99.9%), Corcept Therapeutics Incorporated would be worth roughly what it owes.
Total debt $9.4M against a stock market value of $9.47B.
Distance to default 11.19 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $5.7M (short-term plus half of long-term), stock volatility 64.9%; Altman Z'' 8.76. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
🏦 Institutional Activity
Latest: Q2 2026480
Institutions Holding
+25 vs prior
76.1%
Ownership
+42.48%
130
New
147
Increased
162
Reduced
51
Closed
👔 Insider Trades
25 records| Date | Name | Title | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | WILSON JAMES N | director | S-Sale | 300 | $116.30 | $35K | Filing |
| 2026-10-15 | WILSON JAMES N | director | S-Sale | 3,046 | $115.39 | $351K | Filing |
| 2026-10-15 | WILSON JAMES N | director | S-Sale | 6,654 | $114.48 | $762K | Filing |
| 2026-10-02 | Maduck Sean | officer: see remarks | S-Sale | 8,744 | $116.55 | $1.0M | Filing |
| 2026-10-02 | Maduck Sean | officer: see remarks | S-Sale | 15,843 | $116.12 | $1.8M | Filing |
| 2026-10-02 | Lyon Joseph Douglas | officer: see remarks | S-Sale | 4,744 | $116.54 | $553K | Filing |
| 2026-10-02 | Lyon Joseph Douglas | officer: see remarks | S-Sale | 4,446 | $115.70 | $514K | Filing |
| 2026-10-02 | Vieira Roberto Wandenkolk | officer: president, oncology | S-Sale | 5,147 | $116.58 | $600K | Filing |
| 2026-10-02 | Vieira Roberto Wandenkolk | officer: president, oncology | S-Sale | 2,086 | $115.73 | $241K | Filing |
| 2026-10-02 | Vieira Roberto Wandenkolk | officer: president, oncology | S-Sale | 1,100 | $114.52 | $126K | Filing |
| 2026-10-01 | Maduck Sean | officer: see remarks | S-Sale | 413 | $115.54 | $48K | Filing |
| 2026-10-01 | Lyon Joseph Douglas | officer: see remarks | S-Sale | 810 | $115.40 | $93K | Filing |
| 2026-09-24 | Robb Gary Charles | officer: chief business officer | G-Gift | 5,000 | $— | $0 | Filing |
| 2026-09-24 | Robb Gary Charles | officer: chief business officer | G-Gift | 17,100 | $— | $0 | Filing |
| 2026-09-16 | Vieira Roberto Wandenkolk | officer: president, oncology | S-Sale | 296 | $100.82 | $30K | Filing |
| 2026-09-15 | WILSON JAMES N | director | S-Sale | 2,800 | $111.70 | $313K | Filing |
| 2026-09-15 | WILSON JAMES N | director | S-Sale | 400 | $110.84 | $44K | Filing |
| 2026-09-15 | WILSON JAMES N | director | S-Sale | 6,800 | $110.27 | $750K | Filing |
| 2026-09-14 | Lyon Joseph Douglas | officer: see remarks | S-Sale | 2,188 | $114.12 | $250K | Filing |
| 2026-09-14 | Lyon Joseph Douglas | officer: see remarks | S-Sale | 7,812 | $113.32 | $885K | Filing |
| 2026-09-02 | Vieira Roberto Wandenkolk | officer: president, oncology | S-Sale | 1,606 | $113.72 | $183K | Filing |
| 2026-09-02 | Lyon Joseph Douglas | officer: see remarks | F-Tax Withholding | 72 | $113.38 | $8K | Filing |
| 2026-09-02 | Vieira Roberto Wandenkolk | officer: president, oncology | S-Sale | 1,225 | $115.44 | $141K | Filing |
| 2026-09-02 | Vieira Roberto Wandenkolk | officer: president, oncology | S-Sale | 23,600 | $109.35 | $2.6M | Filing |
| 2026-09-02 | Robb Gary Charles | officer: chief business officer | F-Tax Withholding | 91 | $113.38 | $10K | Filing |
🏛️ Congressional Trades
0 records| Date | Politician | Chamber | Type | Amount | Filing |
|---|---|---|---|---|---|
| No congressional trades found | |||||
🏦 Top Institutional Holders
20 holders| Holder | Shares | Value | Date Reported | Filing | |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12,432,023 | $1.1B | +280,747 | 2026-06-30 | Filing |
| INGALLS & SNYDER LLC | 7,934,507 | $690M | +325,791 | 2026-06-30 | Filing |
| RENAISSANCE TECHNOLOGIES LLC | 5,261,628 | $457M | -421,155 | 2026-06-30 | Filing |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5,044,638 | $439M | +224,070 | 2026-06-30 | Filing |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,172,482 | $363M | +95,286 | 2026-06-30 | Filing |
| Parallel Advisors, LLC | 3,962,177 | $345M | -15,227 | 2026-06-30 | Filing |
| FMR LLC | 3,337,618 | $290M | +147,426 | 2026-06-30 | Filing |
| STATE STREET CORP | 3,279,381 | $285M | +78,435 | 2026-06-30 | Filing |
| AQR CAPITAL MANAGEMENT LLC | 2,582,561 | $225M | +2,176,356 | 2026-06-30 | Filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2,532,198 | $220M | -181,321 | 2026-06-30 | Filing |
| FIRST TRUST ADVISORS LP | 1,829,545 | $159M | -343,831 | 2026-06-30 | Filing |
| TANG CAPITAL MANAGEMENT LLC | 1,500,000 | $130M | — | 2026-06-30 | Filing |
| UBS Group AG | 1,377,658 | $120M | +13,990 | 2026-06-30 | Filing |
| DIMENSIONAL FUND ADVISORS LP | 1,318,821 | $115M | -234,314 | 2026-06-30 | Filing |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,157,580 | $101M | +37,621 | 2026-06-30 | Filing |
| Sixth Street Partners Management Company | 1,157,580 | $101M | +1,157,580 | 2026-06-30 | Filing |
| MORGAN STANLEY | 1,137,559 | $99M | +118,714 | 2026-06-30 | Filing |
| D. E. Shaw & Co., Inc. | 883,001 | $77M | -298,347 | 2026-06-30 | Filing |
| Cerity Partners LLC | 797,119 | $69M | +65,430 | 2026-06-30 | Filing |
| MPM BIOIMPACT LLC | 771,028 | $67M | -214,672 | 2026-06-30 | Filing |